Vimarsana
Biggest News Aggregation in the World

Page 4 - Chief Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chief Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chief Science Today - Breaking & Trending Today

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - Vimarsana News

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 02, 2024 -- Arch Biopartners Inc., , announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and...

Sweet Success: Researchers Crack Sugarcane's Complex Genetic Code - Vimarsana News

Sweet Success: Researchers Crack Sugarcane's Complex Genetic Code

Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance

Sweet Success: Researchers Crack Sugarcane's Complex Genetic Code - Vimarsana News

Sweet Success: Researchers Crack Sugarcane's Complex Genetic Code

Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance

Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204 - Vimarsana News

Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

Marvel Biosciences Corp. , and its wholly owned subsidiary, Marvel Biotechnology Inc. , today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel...

Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204 - Vimarsana News

Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

Marvel Biosciences Corp. , and its wholly owned subsidiary, Marvel Biotechnology Inc. , today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the...